2021
INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA
Blondin N, Fulbright R, Huttner A, Moliterno-Gunel J. INNV-07. TTFIELDS TREATMENT OF GLIOSARCOMA AND RECURRENT ANAPLASTIC OLIGODENDROGLIOMA. Neuro-Oncology 2021, 23: vi106-vi106. DOI: 10.1093/neuonc/noab196.419.Peer-Reviewed Original ResearchYear old womanStable diseaseAnaplastic oligodendrogliomaOlder womenCycles of temozolomideRecurrent anaplastic oligodendrogliomaRecurrent glioblastoma patientsTemporal lobe gliosarcomaTreatment of gliosarcomaGlioma subtypesImproved survival outcomesSmall case seriesStandard of careRight frontal lobeConventional radiation therapyConcurrent temozolomideFurther chemotherapyRadiographic progressionOverall survivalCase seriesInitial diagnosisRadiographic findingsSurvival outcomesSignificant thrombocytopeniaHistorical controls
2019
ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Barkhoudarian G, Blondin N, Chowdhary S, Fonkem E, Vaillant B, Kesari S. ACTR-69. FEASIBILITY STUDY OF THE EMULATE THERAPEUTICS™ VOYAGER SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2019, 21: vi29-vi29. PMCID: PMC6847325, DOI: 10.1093/neuonc/noz175.110.Peer-Reviewed Original ResearchAdverse eventsOutcome measuresDevice-related serious adverse eventsSerious adverse eventsProgression-free survivalSecondary outcome measuresCessation of treatmentFurther prospective studiesPrimary outcome measureStandard of careMulti-center studyMild dysesthesiaSurgical debulkingOverall survivalProspective studyClinical utilityFeasible treatmentPatientsBrain cancerInvestigational deviceMonthsTreatmentGBMSurvivalDebulkingINNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS.
Reddy N, Blondin N. INNV-23. GLIOBLASTOMA AND FACEBOOK: AN ANALYSIS OF PERCEIVED ETIOLOGIES AND TREATMENTS. Neuro-Oncology 2019, 21: vi135-vi135. PMCID: PMC6847258, DOI: 10.1093/neuonc/noz175.566.Peer-Reviewed Original Research
2018
ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Barkhoudarian G, Chowdhary S, Blondin N, Kesari S. ACTR-26. A FEASIBILITY STUDY OF THE NATIVIS VOYAGER® SYSTEM IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology 2018, 20: vi16-vi17. PMCID: PMC6216178, DOI: 10.1093/neuonc/noy148.059.Peer-Reviewed Original ResearchDevice-related adverse eventsAdverse eventsOutcome measuresMaximal tumor debulkingSecond-line therapyProgression-free survivalSecondary outcome measuresFurther prospective studiesPrimary outcome measureStandard of careMulti-center trialInvestigational medical deviceTreatment of glioblastomaClinical utility dataContinual therapyConcurrent therapyOverall survivalProspective studySafety profileTumor debulkingInterim safetyClinical utilityFeasible treatmentPatientsBrain cancer